Works by De Roquancourt, Anne

Results: 16

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin--Cyclophosphamide Regimen.

Published in:

PLoS Medicine, 2007, v. 4, n. 3, p. 0585, doi. 10.1371/journal.pmed.0040090

By:

Bertheau, Philippe;
Turpin, Elisabeth;
Rickman, David S.;
Espie, Marc;
Reyniés, Aurélien;
Feugeas, Jean-Paul;
Plassa, Louis-François;
Soliman, Hany;
Varna, Mariana;
De Roquancourt, Anne;
Lehmann-Che, Jacqueline;
Beuzard, Yves;
Marty, Michel;
Misset, Jean-Louis;
Janin, Anne;
De Thé, Hugues

Publication type:

Article

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Published in:

2013

By:

Groheux, David;
Hatt, Mathieu;
Hindié, Elif;
Giacchetti, Sylvie;
de Cremoux, Patricia;
Lehmann-Che, Jacqueline;
Martineau, Antoine;
Marty, Michel;
Cuvier, Caroline;
Cheze-Le Rest, Catherine;
de Roquancourt, Anne;
Visvikis, Dimitris;
Espié, Marc

Publication type:

journal article

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors.

Published in:

Cancer (0008543X), 2013, v. 119, n. 11, p. 1960, doi. 10.1002/cncr.28020

By:

Groheux, David;
Hatt, Mathieu;
Hindié, Elif;
Giacchetti, Sylvie;
de Cremoux, Patricia;
Lehmann‐Che, Jacqueline;
Martineau, Antoine;
Marty, Michel;
Cuvier, Caroline;
Cheze‐Le Rest, Catherine;
de Roquancourt, Anne;
Visvikis, Dimitris;
Espié, Marc

Publication type:

Article

Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer.

Published in:

JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 24, p. 1879, doi. 10.1093/jnci/djs451

By:

Groheux, David;
Hinde, Elif;
Delord, Marc;
Giacchetti, Sylvie;
Hamy, Anne-sophie;
de Bazelaire, Cedric;
de Roquancourt, Anne;
Vercellino, Laetitia;
Toubert, Marie-Elisabeth;
Merlet, Pascal;
Espié, Marc

Publication type:

Article

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

Published in:

2012

By:

Groheux D;
Hindié E;
Delord M;
Giacchetti S;
Hamy AS;
de Bazelaire C;
de Roquancourt A;
Vercellino L;
Toubert ME;
Merlet P;
Espié M;
Groheux, David;
Hindié, Elif;
Delord, Marc;
Giacchetti, Sylvie;
Hamy, Anne-sophie;
de Bazelaire, Cédric;
de Roquancourt, Anne;
Vercellino, Laetitia;
Toubert, Marie-Elisabeth

Publication type:

journal article

18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.

Published in:

Journal of Nuclear Medicine, 2016, v. 57, n. 4, p. 536, doi. 10.2967/jnumed.115.163907

By:

Groheux, David;
Biard, Lucie;
Giacchetti, Sylvie;
Teixeira, Luis;
Hindié, Elif;
Cuvier, Caroline;
Vercellino, Laetitia;
Merlet, Pascal;
de Roquancourt, Anne;
de Cremoux, Patricia;
Resche-Rigon, Matthieu;
Espié, Marc

Publication type:

Article

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

Published in:

Journal of Nuclear Medicine, 2015, v. 56, n. 6, p. 824, doi. 10.2967/jnumed.115.154138

By:

Groheux, David;
Sanna, Alice;
Majdoub, Mohamed;
de Cremoux, Patricia;
Giacchetti, Sylvie;
Teixeira, Luis;
Espié, Marc;
Merlet, Pascal;
de Roquancourt, Anne;
Visvikis, Dimitris;
Hatt, Mathieu;
Resche-Rigon, Matthieu;
Hindié, Elif

Publication type:

Article

Comparison Between 18F-FDG PET Image--Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer.

Published in:

Journal of Nuclear Medicine, 2013, v. 54, n. 3, p. 341, doi. 10.2967/jnumed.112.108837

By:

Hatt, Mathieu;
Groheux, David;
Martineau, Antoine;
Espié, Marc;
Hindié, Elif;
Giacchetti, Sylvie;
de Roquancourt, Anne;
Visvikis, Dimitris;
Rest, Catherine Cheze-Le

Publication type:

Article

Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse.

Published in:

Journal of Nuclear Medicine, 2012, v. 53, n. 2, p. 249, doi. 10.2967/jnumed.111.094045

By:

Groheux, David;
Hindié, Elif;
Giacchetti, Sylvie;
Delord, Marc;
Hamy, Anne-Sophie;
de Roquancourt, Anne;
Vercellino, Laetitia;
Berenger, Nathalie;
Marty, Michel;
Espié, Marc

Publication type:

Article

Breast Intracystic Papillary Carcinoma: An Update.

Published in:

Breast Journal, 2009, v. 15, n. 6, p. 639, doi. 10.1111/j.1524-4741.2009.00823.x

By:

Calderaro, Julien;
Espie, Marc;
Duclos, Juliette;
Giachetti, Sylvie;
Wehrer, Delphine;
Sandid, Wissam;
Cahen-Doidy, Laurence;
Albiter, Marcella;
Janin, Anne;
de Roquancourt, Anne

Publication type:

Article

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer.

Published in:

Oncogene, 2002, v. 21, n. 49, p. 7593, doi. 10.1038/sj.onc.1205932

By:

Turpin, Elizabeth;
Bieche, Ivan;
Bertheau, Philippe;
Plassa, Louis-Francois;
Lerebours, Florence;
Roquancourt, Anne de;
Olivi, Martine;
Espie, Marc;
Marty, Michel;
Lidereau, Rosette;
Vidaud, Michel;
The, Hughes de

Publication type:

Article

Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.

Published in:

Oncogene, 1999, v. 18, n. 54, p. 7834, doi. 10.1038/sj.onc.1203196

By:

Turpin, Elisabeth;
Dalle, Bruno;
de Roquancourt, Anne;
Plassa, L François;
Marty, Michel;
Janin, Anne;
Beuzard, Yves;
de Thé, Hugues

Publication type:

Article

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.

Published in:

Cancers, 2022, v. 14, n. 5, p. 1331, doi. 10.3390/cancers14051331

By:

Giacchetti, Sylvie;
Faucheux, Lilith;
Gardair, Charlotte;
Cuvier, Caroline;
de Roquancourt, Anne;
Campedel, Luca;
Groheux, David;
de Bazelaire, Cedric;
Lehmann-Che, Jacqueline;
Miquel, Catherine;
Cahen Doidy, Laurence;
Amellou, Malika;
Madelaine, Isabelle;
Reyal, Fabien;
Someil, Laetitia;
Hocini, Hamid;
Hennequin, Christophe;
Teixeira, Luis;
Espié, Marc;
Chevret, Sylvie

Publication type:

Article

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC.

Published in:

Cancers, 2020, v. 12, n. 9, p. 2657, doi. 10.3390/cancers12092657

By:

Campedel, Luca;
Blanc-Durand, Paul;
Bin Asker, Asker;
Lehmann-Che, Jacqueline;
Cuvier, Caroline;
De Bazelaire, Cedric;
Teixeira, Luis;
Becourt, Stephanie;
Ledoux, Florence;
Hocini, Hamid;
Bourstyn, Edwige;
Miquel, Catherine;
Guillerm, Sophie;
Charveriat, Patrick;
Espié, Marc;
De Roquancourt, Anne;
Hamy, Anne-Sophie;
Giacchetti, Sylvie

Publication type:

Article

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Published in:

Breast Cancer Research, 2013, v. 15, n. 3, p. 1, doi. 10.1186/bcr3421

By:

Lehmann-Che, Jacqueline;
Hamy, Anne-Sophie;
Porcher, Raphaël;
Barritault, Marc;
Bouhidel, Fatiha;
Habuellelah, Hanadi;
Leman-Detours, Solenne;
Roquancourt, Anne de;
Cahen-Doidy, Laurence;
Bourstyn, Edwige;
Cremoux, Patricia de;
Bazelaire, Cedric de;
Albiter, Marcela;
Giacchetti, Sylvie;
Cuvier, Caroline;
Janin, Anne;
Espié, Marc;
Thé, Hugues de;
Bertheau, Philippe

Publication type:

Article

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions.

Published in:

Journal of Pathology, 2001, v. 194, n. 4, p. 413, doi. 10.1002/path.902

By:

Ma, Lin;
de Roquancourt, Anne;
Bertheau, Philippe;
Chevret, Sylvie;
Millot, Guy;
Sastre-Garau, Xavier;
Espié, Marc;
Marty, Michel;
Janin, Anne;
Calvo, Fabien

Publication type:

Article

Works by De Roquancourt, Anne

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin--Cyclophosphamide Regimen.

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors.

Prognostic Impact of <sup>18</sup>FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer.

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

<sup>18</sup>F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.

Baseline Tumor <sup>18</sup>F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

Comparison Between <sup>18</sup>F-FDG PET Image--Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer.

Triple-Negative Breast Cancer: Early Assessment with <sup>18</sup>F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse.

Breast Intracystic Papillary Carcinoma: An Update.

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer.

Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy.

Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC.

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions.